(e) MAPE up to 100 per cent allowed while fixing prices of such formulations under DPCO, 1987 against the mark up of 60 per cent allowed under DPCO, 1979.

Supplementary Report of the Kelkar Committee

1418. SHRI JAGESH DESAI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3724 given in the Rajya Sabha on the 29th August 1988 and state:

(a) whether it is a fact that Kelkar Committee has submitted its supplementary report to the Government;

(b) if so, when was the report submitted and what are the main contents of the Report;

(c) what were the total number of communications received from consumer, Medical Associations and Members of Parliament by Kelkar Committee;

(d) what are the details of issues raised these communications;

(e) what are the details of recommendations made on each of these issues; and

(f) by when Government would take decision on the Report and by when the Report would be laid on the Table of the House?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) A large number of representations were received against the recommendations of the Kelkar Committee, which were forwarded to the committee. The supplementary report recently submitted by the committee is under examination.

Price Decontrol on Drug

1419. SHRI JAGESH DESAI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3736 given in the Rajya Sabha on the 29th August, 1988 and state:

(a) whether it is a fact that the landed cost of imported Zinc Bacitracin, Polymixin-B-Sulphate, Flucinolone Acetonide and Triprolidine Hcl was more than Rs. 50 lakhs during the year 1985-86 and 1986-87 based on the information provided;

(b) whether it is also a fact that there is a monopoly production of formulations based on these drugs;

(c) if so, on what basis Kelkar Committee recommended these drugs for price decontrol;

(d) whether it is also a fact that Kelkar Committee did not use any data;

(e) whether it is also a fact that his Ministry did not cross check the facts; and

(f) if so, what steps have been taken to remove these anomalies and what are the details of revised recommendations of the committee?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) A large number of representations were received against the recommendations of Kelkar Committee, which were forwarded to the Committee. The supplementary report recently submitted by the Committee is under examination.

Commission on Sale of Baralgon Pheniramine Glybenclamide and Fursemide

1420 SHRI JAGESH DESAI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3631 given in the Rajya Sabha on the 29th August 1988 and state:

(a) whether it is a fact that none of four bulk drugs i.e. Baralgon Pheniramine, Glybenclamide Fursemide have been sold